Efficacy and safety of nilotinib in patients with kit-mutated metastatic or inoperable melanoma: Final results from the global, single-arm, phase ii team trial (2017) Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, et al. Journal article Second primary malignancies in multiple myeloma: An overview and IMWG consensus (2017) Musto P, Anderson KC, Attal MM, Richardson PG, Badros A, Hou J, Comenzo R, et al. Journal article, Review article Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2017) Moreau P, Miguel JS, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, et al. Journal article Prognostic factors for overall survival of patients with advanced renal cell carcinoma - data from the German prospective RCC-Registry (2017) Goebell P, Mueller L, Staehler M, Mueller M, Frank M, Kruggel L, Jaenicke M, Marschner N Conference contribution Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto) (2017) Untch M, Schneeweiss A, Salat C, Rezai M, Zahm DM, Klare P, Blohmer JU, et al. Conference contribution Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer (2017) Guarneri V, Fasching P, Fernandez Abad M, Garcia-Saenz A, Schneeweiss A, Colleoni M, Petru E, et al. Conference contribution Can contemporary trials in HER2-negative metastatic breast cancer (mBC) detect overall survival (OS) benefit? (2017) Kuemmel S, Jackisch C, Mueller V, Schneeweiss A, Klawitter S, Lux MP Conference contribution Treatment reality and outcome data of patients with advanced papillary renal cell carcinoma: Data from the German prospective RCC-Registry (2017) Staehler M, Mueller L, Goebell P, Overkamp F, Frank M, Kruggel L, Jaenicke M, Marschner N Conference contribution Interim results from PAZOREAL: A non-interventional study to assess effectiveness and safety of pazopanib and everolimus in the changing mRCC treatment landscape (2017) Bedke J, Welslau M, Boegemann M, Schostak M, Hering-Schubert C, Petzoldt A, Wolf T, et al. Conference contribution Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension (2017) Cwikla JB, Wolin EM, Pavel ME, Phan AT, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution